Rocket Pharmaceuticals Q2 Results: Net income turns positive on PRV sale
Rocket Pharmaceuticals reported a Q2 adjusted EPS of $(0.37), missing analyst estimates, but achieved a headline net income of $123.2 million due to a $178.2 million gain from a Rare Pediatric Disease Priority Review Voucher (PRV) sale. This non-recurring gain significantly boosted the company's …